ConvaTec Group (LON:CTEC) Given New GBX 172 Price Target at JPMorgan Chase & Co.
ConvaTec Group (LON:CTEC) had its price objective hoisted by JPMorgan Chase & Co. from GBX 167 ($2.06) to GBX 172 ($2.12) in a report released on Tuesday, Stock Target Advisor reports. The firm currently has an underweight rating on the stock.
Other equities analysts also recently issued research reports about the company. CSFB increased their price objective on ConvaTec Group from GBX 175 ($2.15) to GBX 180 ($2.22) and gave the stock an underperform rating in a report on Friday, May 1st. Credit Suisse Group increased their target price on ConvaTec Group from GBX 175 ($2.15) to GBX 180 ($2.22) and gave the stock an underperform rating in a research note on Friday, May 1st. Jefferies Financial Group cut their target price on ConvaTec Group from GBX 250 ($3.08) to GBX 240 ($2.95) and set a buy rating on the stock in a research note on Wednesday, May 20th. Shore Capital reissued a hold rating on shares of ConvaTec Group in a research note on Thursday, April 30th. Finally, Royal Bank of Canada raised ConvaTec Group to an outperform rating and increased their target price for the stock from GBX 178 ($2.19) to GBX 245 ($3.02) in a research note on Wednesday, June 10th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. ConvaTec Group presently has an average rating of Hold and an average target price of GBX 214 ($2.63).
CTEC opened at GBX 195.60 ($2.41) on Tuesday. The stock has a fifty day simple moving average of GBX 206.26 and a two-hundred day simple moving average of GBX 198.02. The company has a current ratio of 2.44, a quick ratio of 1.64 and a debt-to-equity ratio of 100.87. The company has a market cap of $3.96 billion and a price-to-earnings ratio of 391.20. ConvaTec Group has a 12-month low of GBX 140.40 ($1.73) and a 12-month high of GBX 225.80 ($2.78).
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes.
Featured Article: Retained Earnings
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.